Prevalence and dynamics of BCR-ABL independent gene mutations in chronic phase CML patients

被引：0
|
作者：
Ruppert, L. [1 ]
Rinke, J. [1 ]
Waldau, A. [1 ]
Hochhaus, A. [1 ]
Ernst, T. [1 ]
机构：
[1] Univ Klinikum Jena, Klin Innere Med 2, Abt Hamatol Onkol, Jena, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V713
引用
收藏
页码：238 / 239
页数：2
相关论文
共 50 条
  • [31] Hasford score correlates with the dynamics of imatinib induced reduction of BCR-ABL transcripts in chronic phase CML.
    Raanani, P
    Ben-Bassat, I
    Itskovich, S
    Gan, S
    Morgulis, Y
    Kneller, A
    Brok-Simoni, F
    Rechavi, G
    Amariglio, N
    Nagler, A
    BLOOD, 2003, 102 (11) : 314B - 314B
  • [32] Molecular response according to type of preexisting BCR-ABL mutations after second line dasatinib therapy in chronic phase CML patients
    Mueller, C.
    Erben, Philipp
    Ernst, Thomas
    Giehl, Michelle
    Schenk, Thomas
    Koffmann, Jana
    Lauber, Stephanie
    Kruth, Jens
    Hanfstein, Benjamin
    Bleickardt, Eric
    Nicaise, Claude
    Hehlmann, Rudiger
    Hochhaus, Andreas
    BLOOD, 2007, 110 (11) : 100A - 101A
  • [33] Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
    Hughes, Timothy
    Saglio, Giuseppe
    Branford, Susan
    Soverini, Simona
    Kim, Dong-Wook
    Mueller, Martin C.
    Martinelli, Giovanni
    Cortes, Jorge
    Beppu, Lan
    Gottardi, Enrico
    Kim, Dongho
    Erben, Philipp
    Shou, Yaping
    Haque, Ariful
    Gallagher, Neil
    Radich, Jerald
    Hochhaus, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : 4204 - 4210
  • [34] Quantitative analyses of BCR-ABL mutations associated with imatinib treatment in CML
    Gruber, F
    Hansen, HH
    Olsen, M
    Eggen, L
    Skogen, B
    Gedde-Dahl, T
    Lundan, T
    Porkka, K
    Simonsson, B
    Markevdrn, B
    Wadenvik, H
    Stenke, L
    BLOOD, 2005, 106 (11) : 566A - 566A
  • [35] Not all imatinib resistance in CML are BCR-ABL kinase domain mutations
    Yuan Wei
    Mats Hardling
    Bob Olsson
    Rahil Hezaveh
    Anne Ricksten
    Dick Stockelberg
    Hans Wadenvik
    Annals of Hematology, 2006, 85 : 841 - 847
  • [36] BCR-ABL is not an immunodominant antigen in CML
    Grünebach, F
    Mirakaj, V
    Müller, MR
    Brümmendorf, T
    Brossart, P
    BLOOD, 2005, 106 (11) : 807A - 808A
  • [37] Not all imatinib resistance in CML are BCR-ABL kinase domain mutations
    Wei, Yuan
    Hardling, Mats
    Olsson, Bob
    Hezaveh, Rahil
    Ricksten, Anne
    Stockelberg, Dick
    Wadenvik, Hans
    ANNALS OF HEMATOLOGY, 2006, 85 (12) : 841 - 847
  • [38] Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Hochhaus, Andreas
    Kim, Dong-Wook
    Martinelli, Giovanni
    Hughes, Timothy P.
    Soverini, Simona
    Branford, Susan
    Muller, Martin C.
    Erben, Philipp
    Haque, Ariful
    Shou, Yaping
    Saglio, Giuseppe
    Radich, Jerald P.
    BLOOD, 2008, 112 (11) : 1103 - 1104
  • [39] BCR-ABL Fluctuation Analysis in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients with MR 4.5
    Pereira, Mariana Pinto
    Vanelli, Tito
    da Silva, Eduardo Gomes
    Americo, Andre Dias
    Burin, Mariana M.
    Soares, Tahiane
    Silla, Lucia
    Daudt, Liane
    Fogliatto, Laura
    BLOOD, 2015, 126 (23)
  • [40] BCR-ABL transcript levels and BCR-ABL/BCR transcript ratios in CML patients with good or bad response to treatment.
    Moravcová, J
    Regner, J
    Brezinová, J
    Klamová, H
    BLOOD, 2001, 98 (11) : 264B - 264B
12345